ENTYCE® (capromorelin oral solution)

ENTYCE is commercially available to veterinarians in the United States. ENTYCE is the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs to treat inappetence caused by chronic and acute conditions.


News in Brief

  • Entyce is a ghrelin receptor agonist that works by mimicking the effect of ghrelin, the hunger hormone. Like naturally occurring ghrelin, ENTYCE binds to specific receptors in the hypothalamus and affects signaling to cause the feeling of hunger
  • Inappetence presents as decreased appetite, complete lack of appetite or altered eating patterns in more than 10 million dogs in the United States annually
  • The therapeutic is available as a once-daily, flavored oral solution in 10 mL, 15 mL and 30 mL bottles

“We know improper food intake inhibits the overall health of the dog and has a negative impact on a dog’s quality of life. Nutrition is so imperative, veterinarians and pet owners often use appetite as a fifth vital sign and go to great lengths to address inappetence. Entyce was developed specifically to stimulate appetite and provides the first therapeutic based on the natural physiology of appetite.”

Ernst Heinen, DVM, PhD

Chief Development Officer, Aratana Therapeutics

Turn on Appetite

Visit the ENTYCE website to view safety and efficacy data, download resources and learn how to order.

Inappetence Fact Sheet

Learn how to recognize the signs of inappetence caused by chronic and acute conditions.

ENTYCE Mechanism of Action

Watch how ENTYCE works by mimicking ghrelin, the naturally occurring hunger hormone.


ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency.  Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

Recent News Posts

View All